PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES

• Guillermo Garcia-Manero,
• Valeria Santini,
• Pierre Fenaux,
• Takahiro Suzuki,
• Mikkael Sekeres,
• Jun He,
• Ronit Barkalifa,
• Carlos Vigil,
• Thomas Prebet,
• Rami S. Komrokji,
• Aristoteles Giagounidis

Affiliations

Guillermo Garcia-Manero

1 MD Anderson Cancer Center, Houston, TX, United States

Valeria Santini

2 MDS Unit, AOU Careggi, University of Florence, Florence, Italy

Pierre Fenaux

3 Service d’Hématologie Séniors, Assistance Publique-Hôpitaux de Paris and Université Paris, Paris, France

Takahiro Suzuki

5 Kitasato University School of Medicine, Sagamihara-shi, Kanagawa, Japan

Mikkael Sekeres

6 Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States

Jun He

7 Bristol Myers Squibb, Summit, NJ, United States

Ronit Barkalifa

7 Bristol Myers Squibb, Summit, NJ, United States

Carlos Vigil

7 Bristol Myers Squibb, Summit, NJ, United States

Thomas Prebet

7 Bristol Myers Squibb, Summit, NJ, United States

Rami S. Komrokji

8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States

Aristoteles Giagounidis

9 Marien Hospital Düsseldorf, Düsseldorf, Germany